Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME Information
- 1 Basic Neuroscience
- 2 Psychosis and Schizophrenia and Antipsychotics
- 3 Unipolar Depression and Antidepressants
- 4 Bipolar Disorder and Mood Stabilizers
- 5 Anxiety Disorders and Anxiolytics
- 6 Chronic Pain and its Treatment
- 7 Disorders of Sleep and Wakefulness and Their Treatment
- 8 Attention Deficit Hyperactivity Disorder (ADHD) and its Treatment
- 9 Dementia and Cognitive Function and its Treatment
- 10 Substance Use and Impulsive Compulsive Disorders and their Treatment
- Optional Posttests and CME Certificates
- Index
- References
9 - Dementia and Cognitive Function and its Treatment
Published online by Cambridge University Press: 19 October 2021
Book contents
- Stahl’s Self-Assessment Examination in Psychiatry
- Stahl’s Self-Assessment Examination in Psychiatry
- Copyright page
- Contents
- Introduction/Preface
- CME Information
- 1 Basic Neuroscience
- 2 Psychosis and Schizophrenia and Antipsychotics
- 3 Unipolar Depression and Antidepressants
- 4 Bipolar Disorder and Mood Stabilizers
- 5 Anxiety Disorders and Anxiolytics
- 6 Chronic Pain and its Treatment
- 7 Disorders of Sleep and Wakefulness and Their Treatment
- 8 Attention Deficit Hyperactivity Disorder (ADHD) and its Treatment
- 9 Dementia and Cognitive Function and its Treatment
- 10 Substance Use and Impulsive Compulsive Disorders and their Treatment
- Optional Posttests and CME Certificates
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Stahl's Self-Assessment Examination in PsychiatryMultiple Choice Questions for Clinicians, pp. 321 - 350Publisher: Cambridge University PressPrint publication year: 2019
References
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 13)1Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 13)1Google Scholar
Woolf, NJ, Butcher, LL. Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 2011;221(2): 488–98.2CrossRefGoogle ScholarPubMed
References
Barnes, DE, Yaffe, K, Byers, AL, et al. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012;69(5):493–8.1Google Scholar
Pomara, N, Bruno, D, Sarreal, AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012;169: 523–30.2CrossRefGoogle ScholarPubMed
References
Atwood, CS, Bishop, GM, Perry, G et al. Amyloid beta: a vascular sealant that protects against hemorrhage? J Neurosci Res 2002;70(3):356.1Google Scholar
Kokjohn, TA, Maarfouf, CL, Roher, AE. Is Alzheimer’s disease amyloidosis the result of a repair mechanism gone astray? Alzheimer’s Dementia 2012;8(6):574–83.2Google Scholar
Kumar, DK, Choi, SH, Washicosky, KJ et al. Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med 2016;8(340):340ra72.3Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 13)1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, the prescriber’s guide, fifth edition. New York, NY: Cambridge University Press; 2014.2Google Scholar
References
Kotermanski, SE, Johnson, JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J Neurosci 2009;29(9): 2774–9.1Google Scholar
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 13)2Google Scholar
References
For more information about ongoing Alzheimer’s disease clinical trials, including how to enroll in the A4, DIAN-TU, and other studies, please visit the following resources:
Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimer’s Dement 2016;12(4):459–509.1Google Scholar
Godyn´, J, Jon´czyk, J, Panek, D et al. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Res 2016;68:127–38.2Google ScholarPubMed
Harrison, JR, Owen, MJ. Alzheimer’s disease: the amyloid hypothesis on trial. Br J Psychiatry 2016;208(1):1–3.3Google Scholar
Panza, F, Seripa, D, Solfrizzi, V et al. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients. Expert Opin Emerg Drugs 2016;21(4): 377–91.4Google Scholar
References
Alexopoulos, GS, Kiosses, DN, Heo, M, Murphy, CF, Shanmugham, B, Gunning-Dixon, F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005;58(3):204–10.1CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013.(Chapter 13)2Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 13)1Google Scholar
References
McKhann, GM, Knopman, DS, Chertkow, H et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):263–9.1Google Scholar
References
Cummings, JL. Biomarkers in Alzheimer’s disease drug development. Alzheimer Dementia 2011;7:e13–44.1CrossRefGoogle ScholarPubMed
McKhann, GM, Knopman, DS, Chertkow, H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dementia 2011;7: 263–9.2Google Scholar
Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer Dementia 2011;7: 280–92.3Google Scholar
References
Stahl, SM. Stahl’s essential psychopharmacology, fourth edition. New York, NY: Cambridge University Press; 2013. (Chapter 13)1Google Scholar
References
Hodgson, NA, Gitlin, LN, Winter, L, et al. Undiagnosed illness and neuropsychiatric behaviors in community residing older adults with dementia. Alzheimer Dis Assoc Disord 2011;25:109–15.1Google Scholar